Compile Data Set for Download or QSAR
Report error Found 1159 Enz. Inhib. hit(s) with all data for entry = 12072
TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676333(US20240166635, Example 54)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676441(US20240166635, Example 131b)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676333(US20240166635, Example 54)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676332(US20240166635, Example 53)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676440(US20240166635, Example 131a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676332(US20240166635, Example 53)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676334(US20240166635, Example 55)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676334(US20240166635, Example 55)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676333(US20240166635, Example 54)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676442(US20240166635, Example 132a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676329(US20240166635, Example 51a | US20240166635, Exampl...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676437(US20240166635, Example 129)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676437(US20240166635, Example 129)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676331(US20240166635, Example 52)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676438(US20240166635, Example 130a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676331(US20240166635, Example 52)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676331(US20240166635, Example 52)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676338(US20240166635, Example 59)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676448(US20240166635, Example 135a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676338(US20240166635, Example 59)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676450(US20240166635, Example 136a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676339(US20240166635, Example 60)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676339(US20240166635, Example 60)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676339(US20240166635, Example 60)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676336(US20240166635, Example 57)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676335(US20240166635, Example 56)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676335(US20240166635, Example 56)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676444(US20240166635, Example 133a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676335(US20240166635, Example 56)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676446(US20240166635, Example 134a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676337(US20240166635, Example 58)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676337(US20240166635, Example 58)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676336(US20240166635, Example 57)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676445(US20240166635, Example 133b)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676336(US20240166635, Example 57)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676336(US20240166635, Example 57)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676344(US20240166635, Example 64b)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676454(US20240166635, Example 138a | US20240166635, Examp...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676343(US20240166635, Example 64a)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676454(US20240166635, Example 138a | US20240166635, Examp...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676345(US20240166635, Example 65)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676456(US20240166635, Example 139a | US20240166635, Examp...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676344(US20240166635, Example 64b)
Affinity DataIC50: 10nMAssay Description:CDK6/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, 2 mM ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676341(US20240166635, Example 62)
Affinity DataIC50: 10nMAssay Description:CDK1/CyclinB kinase inhibitory activity (IC50): 5 μl of various dilutions of test compound in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676451(US20240166635, Example 136b)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676341(US20240166635, Example 62)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676452(US20240166635, Example 137a | US20240166635, Examp...)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676341(US20240166635, Example 62)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676340(US20240166635, Example 61)
Affinity DataIC50: 10nMAssay Description:CDK4/CyclinD1 kinase inhibitory activity (IC50): 5 l of various dilutions of test compound in 1×kinase buffer (20 mM HEPES, pH 7.5, 10 mM MgCl2, 2 mM...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Anrui Biomedical Technology (Guangzhou) Co.

US Patent
LigandPNGBDBM676340(US20240166635, Example 61)
Affinity DataIC50: 10nMAssay Description:CDK2/CyclinE1 kinase inhibitory activity (IC50): 5 μl of various dilutions of test compounds in 1×kinase buffer (50 mM HEPES pH 7.5, 10 mM MgCl2...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Displayed 1 to 50 (of 1159 total ) | Next | Last >>
Jump to: